Hill Dickinson advises Genflow Biosciences on its admission to the Main Market

Law firm Hill Dickinson has advised Genflow Biosciences plc (LON: GENF), the first pure-play longevity biotechnology firm to list in Europe, on a £3.7 million oversubscribed placing and the company’s admission to the standard segment of the main market of the London Stock Exchange.

Genflow is a UK-based biotechnology company focused on the science of longevity and the development of gene therapies, through novel therapeutics, to counteract the effects of ageing and diseases associated with advanced age.

The company is led, and was founded, by Dr Eric Leire, who has two decades of experience in cell and gene therapy and has led several therapy companies, including Enochian Biosciences which is listed on the Nasdaq. Dr Leire has brought together experts in various fields within the longevity sector to establish a strong scientific advisory board which will guide Genflow’s pre-clinical and clinical programmes and provide external perspectives to steer its research and development strategies. 

The Hill Dickinson team was led by Corporate partner Jaspal Sekhon with assistance from Victor Oliynik (associate, Corporate), Oliver Hart (paralegal, Corporate), Jamie Foster (partner, Health and Life Sciences), Caroline Lorkin (associate, Health and Life Sciences) and Will Steed (senior associate, Employment).

Commenting on the deal, Jaspal Sekhon said: “We are delighted to have supported Genflow Biosciences on its successful IPO. As a firm, our multidisciplinary life sciences team has been active in the longevity sector for several years advising a number of companies and investors on a wide range of mandates. This deal showcases our deep sector knowledge and our ability to combine our capital markets and life sciences expertise to support businesses in this innovative sector. We wish Genflow Biosciences every success in this exciting next chapter and continuing to support the company’s growth plans.”